References
- Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science. 2021 Jan 12;371(6530):741–745.
- Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. Expert Rev Vaccines. 2020;19(7):661–686.
- Thompson KM, Kalkowska DA. Reflections on modeling poliovirus transmission and the polio eradication endgame. Risk Anal. 2020;41(2):229–247.
- Thompson KM, Kalkowsa DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: 1. consequences of policy decisions to respond using nonpharmaceutical interventions. Expert Rev Vaccines. 2021; doi:10.1080/14760584.2021.1891888 .
- Pourbohloul B, Meyers LA, Skowronski DM, et al. Modeling control strategies of respiratory pathogens. Emerg Infect Dis. 2005 Aug;11(8):1249–1256.
- Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature. 2006 Jul 27;442(7101):448–452.
- Germann TC, Kadau K, Longini IM Jr., et al. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA. 2006 Apr 11;103(15):5935–5940.
- Halloran ME, Ferguson NM, Eubank S, et al. Modeling targeted layered containment of an influenza pandemic in the United States. Proc Natl Acad Sci USA. 2008 Mar 25;105(12):4639–4644.
- Gumel AB, McCluskey CC, An WJ. SVEIR model for assessing potential impact of an imperfect anti-SARS vaccine. Math Biosci Eng. 2006 Jul;3(3):485–512.
- Podder CN, Gumel AB, Bowman CS, et al. Mathematical study of the impact of quarantine, isolation and vaccination in curtailing an epidemic. J Biol Syst. 2007;15(2):185–202.
- Institute of Medicine. Modeling community containment for pandemic influenza: A letter report Washington, DC: National Academies Press; 2006 [cited 2020 Nov 1]. Available from: https://www.nap.edu/catalog/11800/modeling-community-containment-for-pandemic-influenza-a-letter-report
- Centers for Disease Control and Prevention. Interim pre-pandemic planning guidance: community strategy for pandemic influenza mitigation in the United States: early, targeted, layered use of nonpharmaceutical interventions 2007 [cited 2020 Nov 1]. Available from: https://stacks.cdc.gov/view/cdc/11425
- World Health Organization. WHO global influenza preparedness plan: the role of WHO and recommendations for national measures before and during pandemics 2005 [cited 2020 Nov 12]. Available from: https://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_5.pdf
- Plotkin SA. Vaccines for epidemic infections and the role of CEPI. Hum Vaccin Immunother. 2017 Dec 2;13(12):2755–2762.
- Moore S, Hill EM, Dyson L, et al. Modelling optimal vaccination strategy for SARS-CoV-2 in the UK. medRxiv. 2020.09.22.20194183; doi:10.1101/2020.09.22.20194183.
- Gallagher ME, Sieben AJ, Nelson KN, et al. Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates. medRxiv. 2020:2020.08.07.20170456 2020; 10.1101/2020.08.07.20170456
- Makhoul M, Ayoub HH, Chemaitelly H, et al. Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses. Vaccines (Basel). 2020 Nov 9;8(4):4.
- Bubar KM, Reinholt K, Kissler SM, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021 Feb 26;371(6532):916–921. 10.1126/science.abe6959
- Oshinsky DM. Polio: an American Story. New York: Oxford University Press; 2005.
- Offit PA. The cutter incident: how America’s first polio vaccine led to the growing vaccine crisis. New Haven: Yale University Press; 2005.
- Roser M, Ritchie H, Ortiz-Ospina E. World population growth 2013 [ updated May 2019; cited 2020 Oct 16]. Available from: https://ourworldindata.org/world-population-growth
- Mazareanu J. Global air traffic - scheduled passengers 2004-2021 [updated Nov 2020; cited 2020 Nov 8]. Available from: https://www.statista.com/statistics/564717/airline-industry-passenger-traffic-globally/#statisticContainer
- Anon. World development indicators: air transport, passengers carried: the World Bank; 2020 [cited 2020 Nov 8]. Available from: https://data.worldbank.org/indicator/IS.AIR.PSGR?end=2018&name_desc=false&start=1970
- Bodian D. Neutralization of three immunological types of poliomyelitis virus by human gamma Globulin. Proc Soc Exp Biol Med. 1949 Oct;72(1):259–261.
- Bodian D, Morgan IM, Howe HA. Differentiation of types of poliomyelitis viruses; the grouping of 14 strains into three basic immunological types. Am J Hyg. 1949 Mar;49(2):234–245.
- Enders JF, Weller TH, Robbins FC. Cultivation of the lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science. 1949 Jan 28;109(2822):85–87.
- Salk JE, Youngner JS, Ward EN. Use of color change of phenol red as the indicator in titrating poliomyelitis virus or its antibody in a tissue-culture system. Am J Hyg. 1954 Sep;60(2):214–230.
- Meldrum M. ‘A calculated risk’: the salk polio vaccine field trials of 1954. BMJ. 1998 Oct 31;317(7167):1233–1236.
- Marks HM. The 1954 salk poliomyelitis vaccine field trial. Clin Trials. 2011 Apr;8(2):224–234.
- Anon. Polio and Eli Lilly and Company. Indiana historical society; 2012. [cited 2020 Nov 15]. Available from: https://www.indianahistory.org/wp-content/uploads/361af7a2729f0dceacf4e2d77469e737.pdf
- Koprowski H. First decade (1950–1960) of studies and trials with the polio vaccine. Biologicals. 2006;34(2):81–86. 2006/06/01/
- Thompson KM, Duintjer Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal. 2006;26(6):1423–1440.
- Sutter RW, Kew OM, Cochi SL, et al. Poliovirus vaccine – live. In: Plotkin SA, Orenstein WA, Offit PA, et al., editors. Plotkin’s vaccines. Sixth ed, Philadelphia: Saunders Elsevier; 2017. p. 866–917.
- Bandyopadhyay AS, Garon J, Seib K. et al. Polio vaccination: past, present and future. Future Microbiol. 2015;10(5):791–808.
- World Health Assembly. Global eradication of poliomyelitis by the year 2000 (resolution 41.28) Geneva: world health organization; 1988 [cited 2019 Jun 4]. Available from: http://www.who.int/csr/ihr/polioresolution4128en.pdf
- World Health Organization. Global Polio Eradication Initiative: Strategic plan 2004-2008 Geneva 2004 [cited 2021 Feb 10]. Available from: https://apps.who.int/iris/handle/10665/42850
- World Health Organization. Global Polio Eradication Initiative - Strategic Plan 2010-2012 Geneva2010 [cited 2021 Feb 10]. Available from: https://apps.who.int/iris/handle/10665/70373
- World Health Organization Global Polio Eradication Initiative. Polio eradication and endgame Strategic Plan (2013-2018) 2013 [cited 2019 Jun 4]. Available from: http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf
- World Health Organization Global Polio Eradication Initiative. Polio eradication and endgame strategic plan (2019-2023) 2019 [cited 2019 Jun 4]. Available from: http://polioeradication.org/wp-content/uploads/2019/05/polio-endgame-strategy-2019-2023.pdf
- Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471–1505.
- Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines. 2012 Apr;11(4):449–459.
- Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Expert Rev Vaccines. 2014;13(2):221–234.
- Kew OM, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296(5566):356–359.
- Duintjer Tebbens RJ, Pallansch MA, Kim J-H, et al. Review: oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. 2013;23(4):680–702.
- World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1) Geneva: world Health Organization; 2008 [cited 2019 Jun 4]. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf
- World Health Organization. 14th meeting of the global commission for certification of poliomyelitis eradication (GCC), Bali, Indonesia, 20-21 September, 2015 Summary of findings, decisions and recommendations 2015 [cited 2020 Jun 1]. Available from: http://polioeradication.org/wp-content/uploads/2016/07/1Report.pdf
- World Health Organization. Report from the twentieth meeting of the global commission for certification of poliomyelitis eradication, Geneva, Switzerland, 17-18 October 2019 2019 [cited 2019 Dec 31]. Available from: http://polioeradication.org/wp-content/uploads/2016/07/20th-meeting-of-the-Global-Commission-for-the-Certification-of-Eradication-of-Poliomyelitis-17-18-October-2019.pdf
- Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - Worldwide, 2016. MMWR. 2016 September 9;65(35):934–938.
- Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Med J Med. 2008;10(8):190.
- Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. Expert Rev Vaccines. 2017;16(6):577–586.
- Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines. 2018;17(8): 739–751. 2018/08/03
- Thompson KM, Kalkowska DA. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). Expert Rev Vaccines. 2019;18(7): 725–736. 2019/07/03
- World Health Organization Global Polio Eradication Initiative. Strategy for the response to type 2 circulating vaccine-derived poliovirus 2020–2021: Addendum to the Polio eradication and endgame strategic plan (2019-2023) 2020 [ cited 2020 Mar 10]. Available from: http://polioeradication.org/wp-content/uploads/2020/04/Strategy-for-the-response-to-type-2-circulating-Vaccine-Derived-Poliovirus-20200406.pdf
- Kalkowska DA, Pallansch MA, Wilkinson A, et al. Updated characterization of poliovirus outbreak response strategies for 2019-2029: impacts of the use of novel OPV2 strains. Risk Anal. 2021;41(2):329–348.
- Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiol 2016;11(12):1549–1561.
- Gorbalenya AE, Baker SC, Baric RS, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiol 2020;5:536–544.
- Le T T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020 May;19(5):305–306.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–2615.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403–416.
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99–111.
- Zimmer C, Corum J, Wee S-L. Coronavirus vaccine tracker: New York Times; 2020 [cited 2020 Nov 9]. Available from: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
- Burton DR, Walker LM. Rational vaccine design in the time of COVID-19. Cell Host Microbe. 2020 May 13;27(5):695–698.
- Kalkowska DA, Wassilak SGF, Cochi SL, et al. Global transmission of live polioviruses: updated integrated dynamic modeling of the polio endgame. Risk Anal. 2021;41(2):248–265.
- Kalkowska DA, Pallansch MA, Cochi SL, et al. Updated characterization of post-OPV cessation risks: lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart. Risk Anal. 2021;41(2):320–328.
- Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, et al. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23(4):703–749.
- World Bank. World Bank list of economies (June 2019) 2019 [ cited 2019 Jul 17]. Available from: http://databank.worldbank.org/data/download/site-content/CLASS.xls
- World Health Organization. WHO/UNICEF estimated coverage time series: WHO and UNICEF; 2020 [cited 2020 Jul 24]. Available from: http://www.who.int/entity/immunization/monitoring_surveillance/data/coverage_estimates_series.xls
- Thompson KM, Pallansch MA, Duintjer Tebbens RJ, et al. Preeradication vaccine policy options for poliovirus infection and disease control. Risk Anal. 2013;33(4):516–543.
- Thompson KM, Duintjer Tebbens RJ, Pallansch MA, et al. Polio eradicators use integrated analytical models to make better decisions. Interfaces. 2015 January-February;45(1):5–25.
- Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet. 2007 Apr 21;369(9570):1363–1371.
- Thompson KM, Pallansch MA, Duintjer Tebbens RJ, et al. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. 2013;33(4):647–663.
- Barrett S. Polio eradication: strengthening the weakest links. Health Aff. 2009;28(4):1079–1090.